Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Lis Winter, Lea Pawlowsky, Anetta Marcinek, Bettina Brauchle, Amelie Muth, Maryam Kazerani, Agnese Petrera, Roman Kischel, Alica Joana Emhardt, Maja Rothenberg-Thurley, Annika Maria Dufour, Karsten Spiekermann, Michael Andreeff, Naval Daver, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2023-173826

Published: 2023

Journal Articles

D DX41 -Low Expression Mimics Germline DDX41 -Phenotype in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 820.

https://doi.org/10.1182/blood-2023-187419

Published: 2023

Journal Articles

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2023-174059

Published: 2023

Journal Articles

Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Alessia Fraccaroli, Elena Stauffer, Katrin Koch, Klaus Hirschbühl, Stephan Breitkopf, Frank Ziemann, Heidrun Drolle, Maja Rothenberg-Thurley, Annika Maria Dufour, Klaus H. Metzeler, Michael von Bergwelt, Karsten Spiekermann, Andreas Hausmann, Christoph Schmid, Mareike Verbeek, Tobias Herold, Johanna Tischer

Blood (2022) 140 (Supplement 1): 4882–4883.

https://doi.org/10.1182/blood-2022-167299

Published: 2022

Journal Articles

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Blood (2022) 140 (Supplement 1): 936–939.

https://doi.org/10.1182/blood-2022-165395

Published: 2022

Journal Articles

Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia

Christian Rausch, Maja Rothenberg-Thurley, Annika Maria Dufour, Stephanie Schneider, Hanna Gittinger, Maria Cristina Sauerland, Dennis Görlich, Utz Krug, Wolfgang E. Berdel, Bernhard Josef Woermann, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Tobias Herold, Klaus H. Metzeler

Blood (2022) 140 (Supplement 1): 3408–3409.

https://doi.org/10.1182/blood-2022-167022

Published: 2022

Journal Articles

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Giulia Maggioni, MD, Cristina Astrid Tentori, MD, Maria Teresa Voso, MD, Sonja Heibl, MD, Klaus H. Metzeler, MD, Jan Moritz Middeke, MD, Joana Desterro, Maria Carmo-Fonseca, Erica Travaglino, Paola Fazi, MD, Alfonso Piciocchi, MS, Annika Maria Dufour, PhD, Jordi Esteve, Marta Pratcorona, MD, Valentina Mancini, MD, Federico Lussana, MD, Karsten Spiekermann, Christian Thiede, MD, Friedrich Stolzel, MD, Aida Botelho de Sousa, Mar Tormo, Pamela Acha, Montserrat Arnan, Nicola Fracchiolla, MD, Marcus Hentrich, Christoph Sippel, Bernhard Heilmeier, Marcos Lemos, Albertina Nunes, Sonia Matos, Marina Diaz, Ana Garrido, MD, David Gallardo, MD, Susana Vives, MD, Olga Salamero, Elisabetta Todisco, MDPhD, Claudia Basilico, MD, Francesco Passamonti, Sigrid Machherndl-Spandl, MD, Lisa Pleyer, Jorge Sierra, Francesc Solé, PhD, Matteo Giovanni Della Porta, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-140494

Published: 2020

Journal Articles

PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

Klaus H. Metzeler, MD, Maja Rothenberg-Thurley, PhD, Dennis Görlich, PhD, Maria Cristina Sauerland, Annika Maria Dufour, PhD, Stephanie Schneider, PhD, Marion Subklewe, MD, Jan Braess, MD, Bernhard J. Wörmann, MD, Wolfgang E. Berdel, Prof., MD, Utz Krug, MD, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, MD, Tobias Herold, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137487

Published: 2020

Journal Articles

NPM1 Variant Allele Frequency and Outcomes in AML

Blood (2018) 132 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2018-99-112549

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML

Veit Bücklein, MD, Thomas Köhnke, MD, Frauke Schnorfeil, PhD, Klaus H. Metzeler, MD, Nikola P Konstandin, PhD, Annika Maria Dufour, PhD, Cristina Sauerland, Wolfgang Hiddemann, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2018-99-119065

Published: 2018

Journal Articles

Comparison of FLT3-ITD Detection By High-Throughput Amplicon Sequencing to Routine Diagnostics - a Retrospective Analysis of AMLCG Study Patients

Katrin Reiter, MSc, Max Hubmann, MD, Egor Harin, Sebastian Vosberg, Kathrin Bräundl, Bianka Ksienzyk, Stephanie Schneider, PhD, Annika Maria Dufour, PhD, Evelyn Zellmeier, Stefan K. Bohlander, MD, Christina Sauerland, Dipl.-Math, Wolfgang E Berdel, MD, Bernhard J Wörmann, MD, Thomas Büchner, MD, Jan Braess, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Philipp A. Greif, MD

Blood (2016) 128 (22): 1682.

https://doi.org/10.1182/blood.V128.22.1682.1682

Published: 2016

Journal Articles

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Blood (2015) 126 (23): 3815.

https://doi.org/10.1182/blood.V126.23.3815.3815

Published: 2015

NARROW

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

D DX41 -Low Expression Mimics Germline DDX41 -Phenotype in Acute Myeloid Leukemia

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

NPM1 Variant Allele Frequency and Outcomes in AML

Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML

Comparison of FLT3-ITD Detection By High-Throughput Amplicon Sequencing to Routine Diagnostics - a Retrospective Analysis of AMLCG Study Patients

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only